TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactory completion of dosing \& efficacy assessments in ISIS 420915-CS2~Exclusion Criteria:~* Any new condition or worsening of existing condition that could make the patient unsuitable for participation, or interfere with the patient participating in and/or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Previous Placebo-Inotersen 300 mg (Type: EXPERIMENTAL): Participants received subcutaneous (SC) doses of 300 milligrams (mg) inotersen once weekly for up to 260 weeks. Participants who received inotersen-matching placebo in the previous study- ISIS 420915-CS2 (NCT01737398) were included in this group.
- Previous Inotersen-Inotersen 300 mg (Type: EXPERIMENTAL): Participants received SC doses of 300 mg inotersen once weekly for up to 260 weeks. Participants who received inotersen in the previous study- ISIS 420915-CS2 were included in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1) Chronic hepatitis with spontaneous manifest HE (mental state grade 1 or 2 according to the West Haven criteria) and an NCT-A performance time \>30 seconds;~* 2) Hyperammonemia (venous ammonia concentration \>50 mmol/L);~* 3) Cooperative, hospitalised, adult patients with liver cirrhosis diagnosed by clinical, histological and ultrasonographic findings (reduced dimensions of the liver as well as splenomegaly) and oesophageal varices at stage II and III observed by endoscopy.~Exclusion Criteria:~* 1) Major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis;~* 2) Acute superimposed liver injury;~* 3) Patient with other neurological disease and metabolic disorders, diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease;~* 4) Alcoholic -toxic cirrhosis because toxic brain damage may interfere with the assessment of HE;~* 5) Severe HE;~* 6) Administration of anti-HE medications such as neomycin, branched-chain amino acids;~* 7) Any additional precipitating factors such as high protein intake (additional high-protein meals), constipation or intake of psycho stimulants, sedatives, antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil), beta-adrenergic blockers, neuromuscular blocking agents, certain antibiotics;~* 8) Patients with fever, sepsis or shock were also excluded to avoid variations caused by body temperature;~* 9) Illiteracy.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Study Arms:
- ACETYL-L-CARNITINE (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained from subject's parents or legally acceptable representative before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)~* Pre-pubertal status (males aged from 4 to 11 \[both inclusive\], females aged from 4 to 9 \[both inclusive\]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males~* Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used)~* Height below 3 percentile~* Bone age below or equal to 12 year~* Epiphyses confirmed as open in patients at least 10 years or more of age~Exclusion Criteria:~* Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone))~* Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated)~* Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone~* Bone age is advanced over chronological age more than 3 years~* Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia~* Prior history of intracranial hypertension~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- hGH:12months treatment (Type: EXPERIMENTAL): None
- hGH: 6 month un-treatment + 6 month treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic graft versus host disease (GVHD) as defined by the National Institutes of Health (NIH) criteria~* Ocular symptoms of NIH eye score 2 or greater:~  * Score 2: Moderate dry eye symptoms partially affecting activities of daily living (ADL) (requiring drops \> 3 x per day or punctal plugs), WITHOUT vision impairment~ * Score 3: Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms OR loss of vision caused by keratoconjunctivitis~* No new systemic immunosuppressive medications within 1 month prior to enrollment~* Subject has the ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Absolute neutrophil count \< 1000/ul~* Known hypersensitivity or allergy to contact lenses~* Evidence of any active viral, bacterial, or fungal infection in the eyes that is progressive despite appropriate treatment~* Treatment with contact lenses within the previous 3 months for any indication~* Active psychiatric disorder, substance abuse or any other reason that would interfere with compliance with the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Bandage Contact Lenses (Type: EXPERIMENTAL): Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients, \>=18 years of age with HIV-1 infection;~* previously treated with antiretroviral agents.~Exclusion Criteria:~* prior use of Fuzeon or T-1249;~* inability to self-inject;~* active, untreated opportunistic infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to extraction of data according to the protocol)~* Male or female patients at least 18 years of age at time of informed consent~* Diagnosis of T2DM (type 2 diabetes mellitus)~* Xultophy® initiation prescribed at least 6 months before inclusion in this study (i.e., date of signed informed consent). Patients may or may not be continuing Xultophy® at study inclusion~* Minimum available data:a.) At the time of Xultophy® prescription: HbA1c value (or if unavailable, the most recent HbA1c value within 6 months before the first Xultophy® prescription);b.) At 6 months plus/minus 45 days after first Xultophy® prescription: HbA1c value~Exclusion Criteria:~* Type 1 diabetes~* Previous participation in this study. Participation is defined as having provided informed consent~* Participation in a clinical trial within 6 months before or 12 months after the first Xultophy® prescription (Participation in a non-interventional study is not an exclusion criteria)~* Mental incapacity, unwillingness or inability to provide informed consent, or language barriers precluding adequate understanding or co-operation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia (WM)~* No previous therapy for WM~* Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of greater than or equal to 2 times the upper limit of each institution's normal value~* CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment~* Karnofsky performance status \> 60~* Life expectancy \> 3 months~* AST (SGOT) \< 3 x ULN~* ALT (SGPT) \< 3 x ULN~* Total bilirubin \< 2 x ULN~* Calculated or measured creatinine clearance \> 30mL/minute~* Serum sodium \> 130 mmol/L~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control~* Male subject agrees to use an acceptable method for contraception for the duration of the study~Exclusion Criteria:~* Previous therapy for Waldenstrom's macroglobulinemia~* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~* Hypersensitivity to dexamethasone, boron or mannitol~* Pregnant or breast-feeding women~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bortezomib, Dexamethasone, Rituximab (Type: EXPERIMENTAL): A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~CIED procedure, signs PIC~Exclusion Criteria:~PIC not signed, minor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- TauroPace irrigation group (Type: None): every consecutive CIED placement, revision, extraction conducted with TauroPace
- antiseptic irrigation group (Type: None): every procedure conducted with adjunct antiseptic irrigation, which could be Taurolidine, TauroPace or Hydrogen Peroxide 3%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Body Weight on the Immediate Health of the Pediatric Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Age 2-18 yrs for whom a length and weight is possible -~Exclusion Criteria:Under 2 yrs or over 18 yrs of age or inability to weigh and measure pt~-

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- At Risk Body Weight (Type: None): Children with a BMI greater and equal to 85%
- Normal Body Weight (Type: None): Children with a BMI of 25 to 75%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign and date the informed consent form or, in case of subjects younger than 18 years, the document must also be signed by a legal guardian;~* ≥ 12 years old;~* Suffer from mild to moderated persistent alergic rhinitis;~* Total NIS scale score ≥ 4 points at the screening visit and within at least 4 of the 7 days before the randomization visit;~* Indication for use nasal corticosteroid;~* Present with alergic rhinitis symptoms for at least 2 years;~* May undergo a washout period of at least 2 weeks~Exclusion Criteria:~* Patients with severe alergic rhinitis;~* Patients with severe co-morbidities (at the investigator's criteria);~* Patients with mild to severe persistent asthma;~* Clinical history of infection of the airways 30 days before the study entry;~* Patients with structural changes causing nasal obstruction, such as pronounced nasal septum deviation, nasal polyps or any other type of nasal malformation;~* For female subjects, be pregnant or breastfeeding or planning to become pregnant or unwilling to use safe birth control methods during the study;~* subjects in need of other drugs to treat alergic rhinitis, such as anti-immunoglobulin E, immunotherapy, anti-leukotrienes, oral corticosteroids, inhalant corticosteroids, or any administration route other than cutaneous;~* Active smokers (use of cigarette, pipe, cigar or any other form of tobacco in any amount within the past 3 months before the study entry);~* Participation in another clinical study within the past 12 months;

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone (Type: EXPERIMENTAL): None
- Nasonex® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topic Insulin Accelerates Wound Healing in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~age eligible for study:18 years old-older gender eligible for study:both accepts healthy volunteers:no have a proband with T1DM or T2DM. A proband is an individual with more than one year of diagnosis. have proband with a wound that is difficult to be healed for at least three months.~patients with serum creatinine \<1.5mg/dl~Exclusion Criteria:~Does not satisfy the above inclusion criteria infection diagnosed wound patients with cellulitis, venous stasis, inadequate perfusion, osteomyelitis and patient's inability to attend clinics for follow up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- vehicle cream (Type: PLACEBO_COMPARATOR): Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
- cream insulin (Type: PLACEBO_COMPARATOR): Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both Sexes, Aged 20 Years Or Older~* Japanese Participants With Skin And Soft Tissue Infections, Septicemia, or RIE Known Or Suspected To Be Caused By MRSA~* Written Informed Consent~Exclusion Criteria:~* Participants With Skin and Soft Tissue infections That Can Be Treated By Surgery Alone~* Participants With Pneumonia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-3009 (daptomycin) 4 mg/kg (Type: EXPERIMENTAL): None
- Vancomycin (Type: ACTIVE_COMPARATOR): None
- MK-3009 (daptomycin) 6 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: \> or = 16 years~* Weight: more than 40 Kg~* Autoimmune Hemolytic anemia with clinical and biochemical evidence of hemolysis refractory to treatment, in relapse or steroids dependant~* Idiopathic thrombocytopenic purpura with platelet counts \< 50,000, refractory to treatment, in relapse or steroids dependant~Exclusion Criteria:~* Current viral or bacterial infection.~* Positive serology for HIV, HCV, HBV.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Median Effective Dose (ED50) of Paracetamol and Morphine : A Study of Interaction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA physical status І or ІІ~2. Moderately painful surgery patients~3. postoperative pain more than 3 on a numerical pain score (NPS) -~Exclusion Criteria:~1. contraindication to the use of paracetamol and morphine~2. Pregnancy~3. age younger than 18 yr~4. patient weight less 65kg~5. intra-operative regional anesthesia,~6. intra-operative administration of analgesics other than fentanyl,~7. postoperative pain less than 3 on a numerical pain score (NPS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
- Morphine (Type: EXPERIMENTAL): Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
- Paracetamol-morphine (Type: EXPERIMENTAL): The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete